Epoxomicin, Synthetic-Calbiochem

产品说明

一般描述

An antitumor and anti-inflammatory agent that acts as a potent, highly specific, and irreversible inhibitor of chymotrypsin-like (CT-L), trypsin-like (T-L), and peptidyl-glutamyl peptide hydrolyzing (PGPH) activities of the proteasome. Modifies the proteasomal catalytic subunits LMP-7, MECL1, and Z. Does not affect the activities of non-proteasomal proteases such as trypsin, cathepsin B, or chymotrypsin. A 1 mM (50 µg/90 µl) solution of Epoxomicin, Synthetic (Cat. No. 324801) in DMSO is also available.
An antitumor agent of microbial origin that acts as a potent, highly specific, and irreversible inhibitor of chymotrypsin-like (CT-L), trypsin-like (T-L), and peptidylglutamyl peptide hydrolyzing (PGPH) activities of the proteasome. Modifies the proteasomal catalytic subunits LMP-7, MECL1, and Z. Epoxomicin also displays potent anti-inflammatory activity in vivo.

包装

100 μg in Glass bottle
Packaged under inert gas

生化/生理作用

Product does not compete with ATP.
Reversible: no
Primary Target
CT-L,T-L,PGPH activity of proteasome
Cell permeable: no

警告

Toxicity: Standard Handling (A)

重悬

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 1 month at -20°C.

其他说明

Meng, L., et al. 1999. Proc. Natl. Acad. Sci. USA 96, 10403.
Sin, N., et al. 1999. Bioorg. Med. Chem. Lett. 9, 2283.
Hanada, M., et al. 1992. J. Antibiot. 45, 1746.

法律信息

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

基本信息

产品性质

安全信息